$TVRD News

Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis - Slideshow

Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

Tvardi Therapeutics To Host KOL Webinar On August 19 To Discuss Current Treatment Landscape In Ulcerative Colitis And Persistent Unmet Needs; Event To Feature New Data From Tvardi And Review Of Phase 1 Healthy Volunteer Results Supporting Potential Of TTI-109 In UC

BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Tvardi Therapeutics Increases At-The-Market Offering Program To $9.69M In Shares

Why Is Tvardi Therapeutics Stock Falling Thursday?

Raymond James Upgrades Tvardi Therapeutics to Outperform, Announces $10 Price Target

Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript

Why Is Tvardi Therapeutics Stock Gaining Tuesday?

BTIG Reiterates Buy on Tvardi Therapeutics, Maintains $15 Price Target

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tvardi Therapeutics Announces Phase 1 Results For TTI-109, Next-Gen STAT3 Inhibitor; Co. Plans To Advance TTI-109 Into STAT3-Driven Dermatologic And Gastrointestinal Diseases, Subject To Additional Funding

HC Wainwright & Co. Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $9

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics Q1 EPS $(0.73) Beats $(0.74) Estimate

Tvardi Therapeutics Files Prospectus For Offering $200M Mixed Shelf